Ann: COVID ARDS Trial Topline 60-Day Results, page-731

The shorters HAVE NOT needed inside information to make money on MSB over the last 3-4 years. They just keep making the same bet, over and over again, and it's an easy bet to win with ol' MSB.

Here is the simple proposition:

(a) MSB will get great (or perhaps good, or good-ish) results in its Phase I, II or III trials and/or sign up licensees to excite enough market interest to drive the share price higher, BUT...

(b) MSB will NOT be able to get the ball across the finish line by obtaining an approval that permits them to monetise their product, SO...

(c) Any gains made in the MSB share price via (a) above will disintegrate over time due to (b), creating prime shorting opportunities.

Up till now? That investing thesis has been 100% accurate.

The only real shot MSB had at getting out of this freakin' perpetual cycle was with AGVHD. And we know how that came out. Thanks, FDA.

Novartis signing up for good will stop the SP bleeding, and should lead to some exciting news on trials. But we need APPROVALS! Nothing else pays da bills in the longer term.

So the shorters keep winning.